Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

NextEdge Admin

08 Nov 2024

4 min 1 sec

The National Comprehensive Cancer Network^®(NCCN^®)—an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care—announces the publication of the expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. This closely follows the recent publication of the expanded NCCN Guidelines^®for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric.

Additional cancer types were added to the title and content for both guidelines. These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment.

“These guidelines consolidate expert recommendations on genetic testing to guide patient-provider decisions for improved screening, prevention, and treatment options,” stated Crystal S. Denlinger, MD, Chief Executive Officer, NCCN.

The NCCN Guidelines include information on when genetic testing is recommended, and which type of testing may be best. They detail which hereditary conditions and genetic mutations are associated with elevated cancer risk and include follow-up on what to do for people who have them. Those next steps can include instructions for increased screening, or even preventive surgeries or other interventions.

“NCCN has been pivotal in developing genetics-focused panels for major cancers, creating evidence-based guidelines to support optimal genetic care,” said Mary B. Daly, MD, PhD, FACP, Chair of the NCCN Guidelines Panel. “These active panels continuously incorporate new evidence on genetic syndromes, screening, prevention, and the expanding role of genetic counseling.”

"The recently updated NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric takes into account the latest published research and expert opinions from more than 30 experts on caring for individuals with risk for hereditary cancer," said Samir Gupta, MD, UC San Diego Moores Cancer Center, Chair of the NCCN Guidelines Panel for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. "For the first time, we feature enhanced recommendations for evaluation for endometrial and gastric cancer risk, including:

1) new recommendations for consideration for hereditary cancer screening for all individuals with newly diagnosed endometrial cancer;

2) new recommendations for evaluation and management of CDH1 associated gastric cancer risk;

3) de-implementation of intense colorectal cancer screening for individuals with CHEK2 pathogenic variants; and

4) enhanced recommendations for managing gastric cancer risk in patients with APC pathogenic variants."

The NCCN Guidelines set the recognized standard for cancer care recommendations, with 88 specialized guidelines continuously updated by over 1,900 experts across 33 NCCN institutions, including primary care physicians and patient advocates.